RA
NEO icon

Royce & Associates’s NeoGenomics NEO Stock Holding History

Royce & Associates’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-132,586
Closed -$1.02M – 796
2025
Q3 		$1.02M Sell
132,586
-860,000
-87% -$6.02M 0.01% 664
2025
Q2 		$7.26M Buy
992,586
+134,540
+16% +$1.09M 0.07% 382
2025
Q1 		$8.14M Buy
858,046
+182,180
+27% +$2.27M 0.09% 336
2024
Q4 		$11.1M Buy
675,866
+36,390
+6% +$565K 0.1% 285
2024
Q3 		$9.43M Buy
639,476
+19,780
+3% +$309K 0.09% 330
2024
Q2 		$8.6M Buy
619,696
+44,799
+8% +$635K 0.08% 355
2024
Q1 		$9.04M Sell
574,897
-16,545
-3% -$255K 0.08% 356
2023
Q4 		$9.57M Sell
591,442
-5,300
-0.9% -$86.7K 0.09% 325
2023
Q3 		$7.34M Buy
596,742
+119,192
+25% +$1.77M 0.07% 382
2023
Q2 		$7.67M Buy
477,550
+27,000
+6% +$445K 0.07% 387
2023
Q1 		$7.84M Sell
450,550
-27,000
-6% -$385K 0.08% 370
2022
Q4 		$4.41M Sell
477,550
-289,200
-38% -$2.7M 0.05% 499
2022
Q3 		$6.6M Buy
766,750
+170,300
+29% +$1.69M 0.07% 377
2022
Q2 		$4.86M Buy
596,450
+226,450
+61% +$2.16M 0.05% 480
2022
Q1 		$4.5M Buy
370,000
+305,000
+469% +$6.42M 0.04% 571
2021
Q4 		$2.22M Hold
65,000
– – 0.02% 707
2021
Q3 		$3.14M Sell
65,000
-10,000
-13% -$463K 0.02% 675
2021
Q2 		$3.39M Hold
75,000
– – 0.02% 676
2021
Q1 		$3.62M Sell
75,000
-100,683
-57% -$5.24M 0.02% 663
2020
Q4 		$9.46M Hold
175,683
– – 0.08% 386
2020
Q3 		$6.48M Sell
175,683
-13,500
-7% -$502K 0.07% 413
2020
Q2 		$5.86M Sell
189,183
-34,500
-15% -$956K 0.06% 417
2020
Q1 		$6.18M Sell
223,683
-36,800
-14% -$1.1M 0.08% 316
2019
Q4 		$7.62M Sell
260,483
-23,620
-8% -$562K 0.07% 388
2019
Q3 		$5.43M Sell
284,103
-194,600
-41% -$4.56M 0.05% 467
2019
Q2 		$10.5M Sell
478,703
-8,500
-2% -$187K 0.09% 317
2019
Q1 		$9.97M Buy
487,203
+20,000
+4% +$348K 0.08% 342
2018
Q4 		$5.89M Buy
467,203
+142,503
+44% +$2.12M 0.05% 460
2018
Q3 		$4.98M Sell
324,700
-9,300
-3% -$129K 0.03% 599
2018
Q2 		$4.38M Hold
334,000
– – 0.03% 624
2018
Q1 		$2.73M Sell
334,000
-561,900
-63% -$4.55M 0.02% 769
2017
Q4 		$7.94M Sell
895,900
-60,000
-6% -$553K 0.05% 465
2017
Q3 		$10.6M Hold
955,900
– – 0.07% 374
2017
Q2 		$8.56M Buy
955,900
+348,900
+57% +$2.77M 0.06% 430
2017
Q1 		$4.79M Buy
607,000
+3,000
+0.5% +$24.4K 0.03% 589
2016
Q4 		$5.18M Sell
604,000
-50,000
-8% -$428K 0.03% 566
2016
Q3 		$5.38M Hold
654,000
– – 0.04% 571
2016
Q2 		$5.26M Buy
654,000
+181,000
+38% +$1.45M 0.03% 576
2016
Q1 		$3.19M Buy
473,000
+348,000
+278% +$2.29M 0.02% 726
2015
Q4 		$984K Buy
+125,000
New +$915K 0.01% 941

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Royce & Associates's NEO Position: Q4 2025 in Review

Royce & Associates sold out of NeoGenomics (NEO) in Q4 2025, closing a stake of 132,586 shares — an estimated $1.02M sold.

Royce & Associates first reported a position in NEO in Q4 2015 and held it in 40 quarters. The position peaked at $11.1M in Q4 2024. 256 funds tracked by Wall St. Rank hold NEO as of Q4 2025.

  • Royce & Associates reported no remaining NeoGenomics position as of Q4 2025 after selling out during the quarter.
  • Royce & Associates sold 132,586 NeoGenomics shares in Q4 2025, an estimated $1.02M.
  • Royce & Associates first reported a position in NeoGenomics in Q4 2015 and held it in 40 quarters.
  • Royce & Associates's NeoGenomics position peaked at $11.1M in Q4 2024.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2025.

Based on Royce & Associates's 13F filing for Q4 2025, filed 9 Feb 2026.